Key result
Type I interferons play a dual role in the intestine, promoting innate immunity while also acting as anti-inflammatory immune modulators in conditions like inflammatory bowel disease.
This review highlights the dual role of type I interferons in promoting innate immunity and suppressing immune responses in the intestine, suggesting potential avenues for modulating IFN treatment in intestinal inflammation.
Warrants caution with type I IFN therapies in IBD; extends anti-inflammatory mechanisms but leaves clinical impact open.
Type I interferons are a widely expressed family of effector cytokines that promote innate antiviral and antibacterial immunity. Paradoxically, they can also suppress immune responses by driving production of anti-inflammatory cytokines, and dysregulation of these cytokines can contribute to host-mediated immunopathology and disease progression. Recent studies describe their anti-inflammatory role in intestinal inflammation and the locus containing IFNAR, a heterodimeric receptor for the type I interferons has been identified as a susceptibility region for human inflammatory bowel disease. This review focuses on the role of type I IFNs in the intestine in health and disease and their emerging role as immune modulators. Clear understanding of type I IFN-mediated immune responses may provide avenues for fine-tuning existing IFN treatment for infection and intestinal inflammation.
No takes yet. Share an insight, caveat, or question.
Cho et al. (2014) conducted a review in Intestinal infection and inflammation. Type I interferons was evaluated. Type I interferons play a dual role in the intestine, promoting innate immunity while also acting as anti-inflammatory immune modulators in conditions like inflammatory bowel disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: